TrialBritish journal of cancer2016

Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial.

Ulrich T Hacker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.